Abstract
In 1991, Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) was introduced to assess the expression of Tyrosinase in the peripheral blood of melanoma patients, in order to identify the presence of Circulating Melanoma Cells. To date, hundreds of studies, some of which are reviewed here, were performed to assess the clinical value of tyrosinase expression alone, and/or, in addition to other molecular markers. Unfortunately no consensus on the utility of tyrosinase detection exists. In this paper, we underline the presence of too many variables that may interfere with the detection of circulating melanoma cells: from withdrawal and RNA extraction, to Reverse Transcriptase – Polymerase Chain Reaction and the assays used for the analysis of amplification products.
Keywords: Tyrosinase, melanoma, RT-PCR, peripheral blood
Current Cancer Drug Targets
Title: Tyrosinase Expression as a Molecular Marker for Investigating the Presence of Circulating Tumor Cells in Melanoma Patients
Volume: 10 Issue: 5
Author(s): A. Gradilone, E. Cigna, A.M. Agliano and L. Frati
Affiliation:
Keywords: Tyrosinase, melanoma, RT-PCR, peripheral blood
Abstract: In 1991, Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) was introduced to assess the expression of Tyrosinase in the peripheral blood of melanoma patients, in order to identify the presence of Circulating Melanoma Cells. To date, hundreds of studies, some of which are reviewed here, were performed to assess the clinical value of tyrosinase expression alone, and/or, in addition to other molecular markers. Unfortunately no consensus on the utility of tyrosinase detection exists. In this paper, we underline the presence of too many variables that may interfere with the detection of circulating melanoma cells: from withdrawal and RNA extraction, to Reverse Transcriptase – Polymerase Chain Reaction and the assays used for the analysis of amplification products.
Export Options
About this article
Cite this article as:
Gradilone A., Cigna E., Agliano A.M. and Frati L., Tyrosinase Expression as a Molecular Marker for Investigating the Presence of Circulating Tumor Cells in Melanoma Patients, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517136
DOI https://dx.doi.org/10.2174/156800910791517136 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Signatures for Individualized Treatment of Malignant Tumors
Current Drug Discovery Technologies Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Titanium Dioxide Nanoparticles: a Risk for Human Health?
Mini-Reviews in Medicinal Chemistry Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Subject Index to Volume 9
Current Pharmaceutical Design Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Current Cancer Drug Targets Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model
Anti-Cancer Agents in Medicinal Chemistry The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Challenges in Oral Delivery: Role of P-gp Efflux Pump
Current Drug Therapy